Lichen China
LICN
2 hedge funds and large institutions have $35.1K invested in Lichen China in 2025 Q2 according to their latest regulatory filings, with funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 0 closing their positions.
0% more funds holding
Funds holding: 2 → 2 (0)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
3.02% less ownership
Funds ownership: 4.32% → 1.31% (-3%)
61% less capital invested
Capital invested by funds: $89.3K → $35.1K (-$54.2K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$28.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
-$93K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
UBS Group
Zurich,
Switzerland
| $29.1K | +$28.5K | +6,704 | +1,932% |
|
|
2
Acadian Asset Management
Boston,
Massachusetts
| $6K | -$93K | -21,842 | -93% |
|
LICN Hedge Fund Activity: Q2 2025 in Review
2 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Lichen China (LICN) for Q2 2025, worth a combined $35.1K — down 61% from $89.3K a quarter earlier.
Fund positioning in LICN was balanced in Q2 2025: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 1 trimmed.
The largest buyer was UBS Group, adding an estimated $28.5K. The largest seller was Acadian Asset Management, cutting an estimated $93K.
- 2 institutional investors held Lichen China (LICN) as of Q2 2025, unchanged from Q1 2025.
- Funds reported $35.1K of Lichen China stock for Q2 2025, down 61% quarter-over-quarter.
- 0 funds opened new Lichen China positions in Q2 2025 and 0 closed out.
- The largest Lichen China buyer in Q2 2025 was UBS Group, an estimated $28.5K added.
- The largest Lichen China seller in Q2 2025 was Acadian Asset Management, an estimated $93K sold.
Based on aggregated 13F filings for Q2 2025.